Introduction {#dmw038s6}
============

Cryopreservation of gametes and embryos is an essential aspect of ART. Its widespread application has allowed increased safety and efficacy of IVF treatments. The proportion of cryopreserved embryo transfer cycles compared with fresh cycles is growing in Europe. Overall it has been estimated that cryopreserved cycles contributed to 32% of the transfers in 2011 compared to 28% in 2010. In some countries, such as Switzerland, Finland, Netherlands, Sweden and Iceland, the proportion of cryopreserved embryo transfers is higher than 50% ([@dmw038C62]). The observed differences among European countries are mainly due to policies requiring lower transfer order which, in turn, have led to more supernumerary embryos available for cryopreservation ([@dmw038C26]). The recent systematic application of cryopreservation for new indications such as cycle segmentation (i.e. planned freeze all) ([@dmw038C31]), oocyte banking ([@dmw038C21],[@dmw038C23]) and pre-implantation genetic testing at the blastocyst stage ([@dmw038C102]) likely will contribute, in our opinion, to a further increase in the proportion of cryopreserved cycles in the near future.

Embryo cryopreservation has, however, generated ethical, moral and legal issues. Some countries have enacted specific laws that restrict (e.g. Germany, Switzerland, Austria) or even forbid (Italy with Law 40 in 2004) embryo cryopreservation. As an alternative and in accordance with the legal prohibition of embryo cryopreservation, oocyte cryopreservation had been introduced into routine practice in Italy ([@dmw038C65]; [@dmw038C9],[@dmw038C10], [@dmw038C11]; [@dmw038C69]; [@dmw038C29]; [@dmw038C115]). Not until 2009 did the Italian Constitutional Court (151/2009) declare the constitutionality of embryo cryopreservation. Nevertheless, some couples are concerned about the disposition of cryopreserved embryos ([@dmw038C84]) and therefore prefer to limit the number of oocytes inseminated, with cryopreservation of the remainder ([@dmw038C49]). Oocyte cryopreservation also has emerged as an important method for female fertility preservation for both medical and non-medical indications (reviewed in [@dmw038C30] and [@dmw038C110]).

Since the first pregnancy and delivery with cryopreserved embryos ([@dmw038C114]; [@dmw038C135]), various protocols have been introduced that differ from each other regarding the type and concentration of cryoprotectants, equilibration timing, cooling rates and cryopreservation devices used. Two principal approaches for cryopreservation have been adopted: slow-freezing and vitrification (reviewed by [@dmw038C33]).

Slow-freezing allows for cryopreservation to occur at a sufficiently slow rate to permit adequate cellular dehydration while minimizing intracellular ice formation. The first successful protocol applied in 1972 for mammalian embryo cryopreservation required a cooling rate of \~1°C/min to −70°C ([@dmw038C127]). Embryo cooling performed this way is referred to as equilibrium freezing ([@dmw038C82]). Subsequently, slow-rate cooling was only applied to around −30°C ([@dmw038C130]). With this approach, intracellular water content was converted into small intracellular ice crystals or into a glass. To avoid extensive crystallization, a very rapid warming was required.

Although the first pregnancies with human cleavage-stage embryos were obtained with the use of dimethylsulphoxide (DMSO) as the cryoprotectant ([@dmw038C114] and [@dmw038C135]) this approach was rapidly replaced.

For nearly 20 years the protocol combining 1.5 M propylene glycol (PROH) plus 0.1 M sucrose, as the permeable and non-permeable cryoprotectants, respectively, has been the most widely used ([@dmw038C66]; [@dmw038C112]). The freezing curve adopted requires the use of a programmable freezing machine designed to provide accurate and consistent cooling parameters. Briefly, the sample is exposed to a relatively rapid cooling rate of 2°C/min to around −7°C followed by a manual seeding to induce ice crystal formation in the solution. Then, a consistent slow cooling rate of 0.3--1.0°C/min is applied before the freezing device is plunged into liquid nitrogen after having reached temperatures around −40 to −70°C using the approach of [@dmw038C114] or [@dmw038C66], respectively. Modifications to the concentration of sucrose and the use of other cryoprotectants such as glycerol have been investigated for cryopreservation of oocytes, biopsied embryos and blastocysts ([@dmw038C25]; [@dmw038C37]; [@dmw038C54]; [@dmw038C122]). Detailed analysis of biological principles and development of various slow-freezing procedures have been described previously ([@dmw038C68]).

In contrast to slow-freezing, vitrification is a cryopreservation method that allows solidification of the cell(s) and the extracellular milieu into a glass-like state without the formation of ice. The most widely used vitrification method for mammalian embryos requires the use of high initial concentrations of cryoprotectants, low volumes and ultra-rapid cooling-warming rates. This approach was first introduced in human embryology for cleavage-stage embryos ([@dmw038C83]) and then for oocytes ([@dmw038C60]) and pronuclear-stage embryos ([@dmw038C53]; [@dmw038C103]). In the last 15 years several vitrification protocols have been described, which differ from one another in the type of cryoprotectants (Ethylene glycol \[EG\] and/or DMSO and/or PROH and sucrose and/or Ficoll and/or Trehalose), equilibration and dilution parameters, the carrier tools and the cooling, storage and warming methods (reviewed in [@dmw038C118]). To date the most commonly used protocol for both oocyte and embryo vitrification involves the combination of 15% DMSO, 15% EG and 0.5 M sucrose in a minimum volume (≤1 µl) ([@dmw038C63],[@dmw038C64]). Other fundamental aspects of the technique are related to the cooling and storing method. At present most embryos and oocytes are vitrified by exposing the sample to direct contact with liquid nitrogen (open system) to increase the cooling/warming rates and thus the efficiency of the procedure ([@dmw038C119]). The ability to survive vitrification is in fact strictly dependent on the degree of cellular dehydration and on the rate of warming, rather than on the type and concentration of cryoprotectants used ([@dmw038C55]). High cryosurvival rates of mouse oocytes and embryos have been recently obtained with the use of only non-permeating cryoprotectant and a relatively slow cooling rate, but combined with an ultra-rapid warming ([@dmw038C55]). This study also demonstrates that the osmotic withdrawal of a very large proportion of intracellular water prior to cooling, and not the permeation of cryoprotectant in the cell, is the key for a successful vitrification ([@dmw038C55]).

To avoid potential contamination during open system vitrification, sterile liquid nitrogen can be used ([@dmw038C117]; [@dmw038C90]). Alternatively, specific devices have been designed to avoid direct contact of the samples with the nitrogen either during vitrification (closed system) and/or during storage ([@dmw038C117]; [@dmw038C61]; [@dmw038C52]; [@dmw038C121]; [@dmw038C2]; [@dmw038C91]). Of note, not all closed systems available on the market are completely free of any possible sources of contamination ([@dmw038C119]). On the other hand, a lower degree of cooling/warming rate is generally associated with the use of these systems. To date, neither open nor closed systems have resulted in disease transmission during vitrification. However, to ensure biosafety during cryopreservation, the use of sterile approaches is recommended ([@dmw038C5]), providing that adequate cooling and, particularly, warming rates are still guaranteed.

The objective of the present study was to compare slow-freezing/thawing versus vitrification/warming for cryopreservation of oocytes, embryos and blastocysts. RCTs and relevant observational cohort studies were included in this systematic review and meta-analysis.

This study was performed to support a prioritized clinical question and to provide a review of the evidence for debate and discussion during the consultation for the development of the World Health Organization (WHO) global guidelines: 'Addressing evidence-based guidance on infertility diagnosis, management and treatment.'

Methods {#dmw038s7}
=======

Oocyte cryopreservation: study eligibility criteria {#dmw038s7a}
---------------------------------------------------

RCTs and well-designed cohort or case-control studies were included that compared outcomes following slow-freeze versus vitrification of mature i.e. metaphase II (MII) oocytes from women undergoing ART. Given the paucity of studies making direct comparisons between the two cryopreservation methods, studies comparing slow-freeze or vitrification to fresh oocytes (control group) were also included. Only trials reported in peer-reviewed full publications involving MII oocyte cryopreservation were included; abstracts were excluded. Data from these studies were used to assess the following outcomes: Clinical pregnancy rate (CPR), live-birth rate (LBR) and oocyte cryosurvival rate when reported.

Oocyte cryopreservation: study search methods {#dmw038s7b}
---------------------------------------------

The searches for relevant studies were last performed and completed on 1 August 2016 by two review authors (AL, RM) using the following search terms: (oocyte(s) \[tiab\]) AND (vitrification\[tiab\] OR freezing\[tiab\] OR freeze\[tiab\]) AND (embryo quality\[tiab\] OR survival\[tiab\] OR pregnancy\[tiab\] OR birth\[tiab\]). The search was limited to human studies. Articles were also identified *via* snowball sampling by hand-searching references from systematic reviews. The search returned 806 records, of which 88 were screened manually for relevance. The information about potentially eligible studies was reported in a table describing the characteristics of the studies for assessing the reliability of the results. Full texts of potentially eligible studies were obtained and examined independently by the two different authors; disagreements as to study eligibility were resolved by discussion (all authors). A total of 20 references were included (Fig. [1](#dmw038F1){ref-type="fig"}a).

![Flow charts for a systematic review and meta-analysis comparing slow-freezing versus vitrification of oocytes, embryos and blastocysts in ART. (a) search for relevant studies for oocytes slow-freezing and vitrification (b) search for relevant studies for pronuclear, cleavage-stage embryo and blastocyst slow-freezing and vitrification.](dmw038f01){#dmw038F1}

Oocyte cryopreservation: study descriptions {#dmw038s7c}
-------------------------------------------

### Slow-frozen versus vitrified oocytes: clinical outcomes and cryosurvival {#dmw038s7c_1}

One RCT was identified that randomized women to have an embryo transfer from MII oocytes that were either slow-frozen or vitrified ([@dmw038C107]). Characteristics of this study are described in Table [I](#dmw038TB1){ref-type="table"}. A total of 230 patients with more than nine MII oocytes retrieved were allocated by random number generator to either slow-freezing or vitrification. This results in 30 cases of oocyte thawing and 48 cases of warming (average ages at oocyte retrieval: 32 ± 1 and 31 ± 1 years (mean + SD), respectively). LBRs were not reported. Ongoing CPRs were reported but not defined by minimum gestational age. Table ICharacteristics of the included RCTs comparing reproductive outcomes of slow-freezing versus vitrification.Authors (year)LocationStudy designCryopreservation protocolsStudy groupN°Control groupN°OutcomesRisk of biasJournal: Impact factor[@dmw038C6]TurkeyRandomization of embryosVitrification 16%PrOH + 16% EG + 0.65 M sucrose + 10 mg/ml Ficoll- open systemCleavage stage vitrification234 embryosCleavage stage slow-freezing232 embryoscryosurvival rate, blastocyct formationSerious risk of bias due to randomization method, concealment of allocation, blindingHuman Reproduction: 4.621Slow-freezing: 1.5 M PROH--0.1 M Sucrose[@dmw038C13]ChinaRandomization of sibling oocytesVitrification 15% EG + 15% PROH + 0.5 M sucrose -- open systemOocyte vitrificaiton292 oocytesOocyte slow-freezing123 oocytescryosurvival rateSerious risk of bias due to randomization method, concealment of allocation, blindingSeminars in Reproductive Medicine: 2.113Slow-freezing: 1.5 M PROH + 0.3 M sucrose[@dmw038C20]SpainRandomization of patientsVitrification 15% EG + 15% DMSO + 0.5 M sucrose -- open systemOocyte vitrification295 cyclesOocyte fresh289 cyclesCPR, cryosurvival rateNo serious risk of biasHuman Reproduction: 4.621[@dmw038C27]BelgiumRandomization of patientsVitrification 15% EG + 15% DMSO + 0.5 M sucrose -- closed systemCleavage stage vitrification121 cyclesCleavage stage slow-freezing85 cyclesCPR, LBR, cryosurvival rateNo serious risk of biasHuman Reproduction: 4.621200 embryosSlow-freezing: 1.5 M PROH − 0.1 M Sucrose217 embryos[@dmw038C39]BelgiumRandomization of embryosVitrification 20% EG + 15% DMSO + 0.5 M sucrose -- closed systemCleavage stage vitrification516 cyclesCleavage stage slow-freezing260 cyclesCPR, LBR, cryosurvival rateSerious risk of bias due to randomization method, concealment of allocation, and blindingJournal of Assisted Reproduction and Genetics: 1.772660 embryos395 embryosSlow-freezing: 1.5 M PROH − 0.1 M Sucrose[@dmw038C51]TaiwanRandomization of embryosVitrification 20% EG + 20% DMSO and 0.5 M sucrose -- open systemBlastocyst vitrification81 embryosBlastocyst slow-freezing72 embryoscryosurvial rateSerious risk of bias due to randomization method, concealment of allocation, blindingHuman Reproduction: 4.621Slow-freezing: 5% glycerol + 9% glycerol 0.2 M sucrose[@dmw038C58]USARandomization of embryosVitrification 5.5 M EG + 1 M sucroseBlastocyst vitrification42 cyclesBlastocyst slow-freezing216 cyclesCPR, cryosurvival rateUnclear risk of bias related to random sequence generation, allocation of concealment acceptable, and blindingFertility and Sterility: 4.426Slow freezing: 5% glycerol and 9% glycerol + 0.2 M sucrose141 embryos790 embryos[@dmw038C89]ItalyRandomization of sibling oocytesVitrification 15% DMSO, 15% EG, and 0.5 M sucrose -- closed systemOocyte vitrification90 oocytesOocyte slow-freezing90 oocytesCryosurvival rateSerious risk of bias due to randomization method, concealment of allocation, blindingReproductive Sciences: 2.429Slow freezing: 1.5 mol/L PROH and 0.3 mol/L sucrose[@dmw038C91]ItalyRandomization of sibling oocytesVitrification 15% EG + 15% DMSO + 0.5 M sucrose -- open systemOocyte vitrification168 oocytesOocyte Fresh120 oocytesCryosurvival rateSerious risk of bias due to randomization method, concealment of allocation, and blindingRBM online:2.796[@dmw038C96]IndiaRandomization of embryosVitrification 40% EG + 0.6 M sucrose -- open systemCleavage stage vitrification84 cyclesCleavage stage slow-freezing80 cyclesCPR, cryosurvival rateUnclear risk of bias related to random sequence generation, allocation of concealment acceptable, and blindingRBM online:2.796127 embryosSlow-freezing: 1.5 M PROH- 0.1 M Sucrose120 embryos[@dmw038C98]ItalyRandomization of sibling oocytesVitrification 15% EG + 15% DMSO + 0.5 M sucrose -- open systemOocyte vitrification124 oocytesOocyte Fresh120 oocytesCryosurvival rateSerious risk of bias due to randomization method, concealment of allocation, and blindingHuman Reproduction: 4.621[@dmw038C107]USARandomization of patientsVitrification 15% EG + 15% DMSO + 0.5 M sucrose -- closed systemOocyte vitrification48 cyclesOocyte Fresh30 cyclesCPR, cryosurvival rateSerious risk of bias: related to randomization method, lack of allocation concealment, lack of blindingFertility and Sterility: 4.621349 oocytes238 oocytesSlow-freezing: 1.5 M PROH- 0.3 M Sucrose[@dmw038C133]ChinaRandomization of embryosVitrification 30% EG + 0.5 M sucrose -- open systemCleavage stage vitrification49 embryosCleavage stage slow-freezing52 embryoscryosurvival rateSerious risk of bias due to randomization method, concealment of allocation, and blindingHuman Reproduction: 4.621Slow-freezing: 1.5 M PROH- 0.1 M sucrose/0.2 M sucrose[^1]

Two cohort studies were identified that compared CPRs from slow-frozen versus vitrified autologous oocytes ([@dmw038C38]; [@dmw038C71]). Oocyte cryopreservation was performed in these studies in an unselected population of infertile patients due to law restrictions (Law 40, 2004, Italy).

A secondary analysis was performed focusing on oocyte cryosurvival rate. One RCT ([@dmw038C107]), two RCTs where sibling oocytes were randomized, rather than patients, ([@dmw038C89]; [@dmw038C13]) and three cohort studies ([@dmw038C38]; [@dmw038C47]; [@dmw038C72]) were included.

### Slow-frozen versus *fresh oocytes: clinical outcomes* {#dmw038s7c_2}

No RCTs were identified comparing outcomes following transfer of embryos from oocytes that were either slow-frozen or fresh. Five cohort studies were identified comparing outcomes following transfer of embryos derived from fresh or slow-frozen/thawed oocytes ([@dmw038C15]; [@dmw038C69]; [@dmw038C11]; [@dmw038C12]; [@dmw038C123]).

### Vitrified versus fresh oocytes: clinical outcomes {#dmw038s7c_3}

One RCT was identified that randomized 600 donor recipients to transfer of embryos either from fresh or vitrified/warmed oocytes ([@dmw038C20]). Characteristics of this study are described in Table [I](#dmw038TB1){ref-type="table"}. Ongoing clinical pregnancy at 10--11 weeks of gestation was reported; however, live-birth data were not reported.

Thirteen other studies were identified: five randomized sibling oocytes, rather than patients, to vitrification versus fresh treatments ([@dmw038C19]; [@dmw038C98]; [@dmw038C91]; [@dmw038C105]; [@dmw038C137]), and eight cohort studies ([@dmw038C4]; [@dmw038C85]; [@dmw038C3]; [@dmw038C115]; [@dmw038C43]; [@dmw038C113]; [@dmw038C108]; [@dmw038C32]). Three sibling oocyte RCTs ([@dmw038C19]; [@dmw038C105]; [@dmw038C137]) and two cohort studies ([@dmw038C85] and [@dmw038C32]) were excluded from analysis due to study design ([@dmw038C137]) or data reporting issues ([@dmw038C19]; [@dmw038C85]; [@dmw038C105]; [@dmw038C32]).

The remaining eight studies were grouped together for comparison of clinical outcomes following transfer of embryos arising from oocytes that were exclusively either vitrified or fresh. Five meta-analyses ([@dmw038C88]; [@dmw038C22]; [@dmw038C17]; [@dmw038C44]; [@dmw038C94]) focusing on oocyte cryopreservation were reviewed.

Embryo cryopreservation: study eligibility criteria {#dmw038s8a}
---------------------------------------------------

RCTs and observational cohort studies were included that compared slow-freeze to vitrification of pronuclear embryos, cleavage-stage embryos or blastocysts from women undergoing ART. Only trials reported in peer-reviewed full publications were included; abstracts were excluded. The following outcomes were assessed: CPR, LBR and embryo cryosurvival rate, when reported.

Embryo cryopreservation: study search methods {#dmw038s8b}
---------------------------------------------

The searches for relevant studies were last performed and completed on August first 2016 using the following search terms: (Pronuclear\[tiab\] OR Embryo\[tiab\] OR Blastocyst\[tiab\]) AND (vitrification\[tiab\] OR freezing\[tiab\] OR freeze\[tiab\]) AND (pregnancy\[tiab\] OR birth\[tiab\] OR clinical\[tiab\]). The search was limited to human studies. Articles were also identified by hand searching references from systematic reviews. The search returned 917 records, of which 587 were screened manually for relevance. Full texts of potentially eligible studies were obtained and examined independently by two different authors (RM, DK); disagreements as to study eligibility were resolved by discussion (all Authors). A total of 20 studies were included for this analysis, comparing outcomes following transfer of vitrified versus slow-frozen embryos (Fig. [1](#dmw038F1){ref-type="fig"}b).

Embryo cryopreservation: study descriptions {#dmw038s8c}
-------------------------------------------

### Vitrified versus slow-frozen embryos: clinical outcomes {#dmw038s8c_1}

Only one well-designed RCT comparing clinical outcomes following vitrification versus slow-freezing between randomized women rather than embryos was identified ([@dmw038C27]). Two RCTs ([@dmw038C96] and [@dmw038C58]) comparing clinical outcomes between randomized embryos were also included. Characteristics of these studies are described in Table [I](#dmw038TB1){ref-type="table"}. One additional RCT ([@dmw038C8]) was excluded because clinical outcomes were incomplete. Moreover, a meta-analysis ([@dmw038C1]) focusing on clinical outcomes was reviewed. None of the included studies compared cryopreservation techniques at the pronuclear-stage. Two of the included RCTs were performed at the cleavage-stage ([@dmw038C96]; [@dmw038C27]) and one at blastocyst stage ([@dmw038C58]). The primary outcome measures chosen were CPR and LBRs.

Eleven observational studies reporting clinical pregnancy per cycle and/or per transfer of embryos at different stages of development were pooled and analyzed ([@dmw038C63],[@dmw038C64]; [@dmw038C109]; [@dmw038C76]; [@dmw038C97]; [@dmw038C129]; [@dmw038C106]; [@dmw038C125]; [@dmw038C120] and [@dmw038C77]; [@dmw038C134]; [@dmw038C57]). An additional two studies described by the authors as RCT\'s were not truly randomized studies and were therefore included in the analysis with observational studies ([@dmw038C73] and [@dmw038C111]).

LBR per cycle and/or per transfer was reported in six studies ([@dmw038C63],[@dmw038C64]; [@dmw038C129]; [@dmw038C125]; [@dmw038C77]; [@dmw038C120]; [@dmw038C57]).

### Slow-frozen versus vitrified embryos: survival {#dmw038s8c_2}

A secondary analysis was performed focusing on embryo cryosurvival rate. Seven RCTs ([@dmw038C58]; [@dmw038C51]; [@dmw038C96]; [@dmw038C133]; [@dmw038C6]; [@dmw038C39]; [@dmw038C27]) were included. Characteristics of these studies are described in Table [I](#dmw038TB1){ref-type="table"}. Moreover, 12 observational studies ([@dmw038C63],[@dmw038C64]; [@dmw038C109]; [@dmw038C76]; [@dmw038C73]; [@dmw038C97]; [@dmw038C129]; [@dmw038C106]; [@dmw038C125]; [@dmw038C120] and [@dmw038C77]; [@dmw038C134]; [@dmw038C111]) and two meta-analyses comparing results obtained with vitrification/warming and slow-freezing/thawing ([@dmw038C78]; [@dmw038C59]) were identified.

Assessing the quality of each study {#dmw038s8d}
-----------------------------------

According to the WHO Handbook for Guideline Development ([@dmw038C128]) the quality of each study was assessed. In particular, each RCT was evaluated for the following factors: how randomization was performed, whether there was concealment of allocation, whether participants and personnel were blinded to the intervention and outcome, whether there was complete data reporting, whether an intention to treat analysis was performed and whether any other potential sources of bias existed ([@dmw038C128]). The overall risk of bias was classified as serious, not serious, or unclear and is presented in Table [I](#dmw038TB1){ref-type="table"} for each randomized trial included. The risk of bias is considered serious for all observational studies given the high risk for selection bias and confounding inherent in these study designs.

Data synthesis and meta-analysis {#dmw038s8e}
--------------------------------

Meta-analyses of studies were undertaken to estimate the pooled relative risk ratios (RR) of outcomes including CPR per cycle, CPR per transfer and cryosurvival of thawed/warmed oocytes or embryos. Statistical analyses and construction of forest and funnel plots were performed with Stata version 12.1 (StataCorp, TX, USA). RR and 95% CIs were calculated for each outcome. A random effects model was used for the meta-analysis. Heterogeneity was assessed with the use of the *I*^2^ test. Publication bias was assessed by constructing funnel plots.

Assessment of the quality of the literature as a whole {#dmw038s8f}
------------------------------------------------------

According to the WHO Handbook for Guideline Development ([@dmw038C128]) used to guide methodology in this systematic review, the quality of the literature for each analysis was classified as high, moderate, low or very low. A grade of high indicates that further research is very unlikely to change confidence in the estimate of effect; moderate indicates that further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate; low indicates that further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate; very low indicates that any estimate of effect is very uncertain ([@dmw038C128]).

Factors used to determine the classification for any analysis took into account the following factors: study design, consistency of the results across the available studies, precision of the results (width of the CI), the directness or generalizability of the results across populations, and the likelihood of publications bias.

Results {#dmw038s9}
=======

Oocyte slow-freezing versus vitrification: clinical outcomes and oocyte cryosurvival {#dmw038s9a}
------------------------------------------------------------------------------------

A single RCT ([@dmw038C107]) revealed evidence of a difference in favor of vitrification regarding ongoing pregnancy rate per cycle (RR = 2.81, 95% CI: 1.05--7.51; *P* = 0.039; 48 and 30 cycles, vitrification versus slow-freezing, respectively; low quality evidence) (Fig. [2](#dmw038F2){ref-type="fig"}a) and per warmed/thawed oocyte (RR = 1.14, 95% CI: 1.02--1.28; *P* = 0.018; 260 and 238 oocytes, vitrification versus slow-freezing, respectively; low quality evidence). Limited evidence demonstrated that clinical outcomes following vitrification versus slow-freezing were similar when ongoing pregnancy rate was expressed per embryo transfer (RR = 1.81, 95% CI: 0.71--4.67; *P* = 0.214; 47 and 19 transfers, vitrification versus slow-freezing, respectively; low quality evidence).

![Comparison of slow-freezing versus vitrification: oocytes. (a) Comparison based on CPR/cycle for oocytes: RCT; (b) Comparison based on CPR/cycle for oocytes: cohort studies; (c) Comparison based on oocyte cryosurvival rate: RCTs. CPR, clinical pregnancy rate.](dmw038f02){#dmw038F2}

In two cohort studies ([@dmw038C38]; [@dmw038C71]) the evidence also favored vitrification for CPR per cycle (RR = 1.72, 95% CI: 0.74--3.95; *P* = 0.212; 5460 and 9212 cycles, vitrification versus slow-freezing, respectively; *I*^2^ = 81.5%, very low quality evidence) (Fig. [2](#dmw038F2){ref-type="fig"}b), per transfer (RR = 1.55, 95% CI: 0.82--2.92; *P* = 0.180, two studies; *I*^2^ = 70.0%, very low quality evidence) and per warmed/thawed oocyte (RR = 1.72, 95% CI: 0.84--3.52; *P* = 0.135; 26789 and 49264 oocytes, vitrification *versus* slow-freezing, respectively; very low quality evidence). However, the differences were not statistically significant. Of note the CPR per cycle was relatively low in the unselected population of patients undergoing autologous oocyte cryopreservation due to law restrictions for both approaches, 11.8% and 14.4% for slow freezing and vitrification, respectively.

The superiority of vitrification over slow-freezing was also observed when cryosurvival rates of MII oocytes were compared. In three RCTs ([@dmw038C89]; [@dmw038C13]; [@dmw038C107]) MII cryosurvival rate was 82.3% (602/731) following vitrification/warming and 66.1% (298/451) following slow-freezing/thawing (RR = 1.23, 95% CI: 1.02--1.49; *P* = 0.031; three studies; 1182 oocytes thawed; *I*^2^ = 82.9%, low quality evidence) (Fig. [2](#dmw038F2){ref-type="fig"}c). In the three cohort studies, cryosurvival rate after vitrification was also significantly higher than after slow-freezing (RR = 1.23, 95% CI: 1.11--1.36, *P* \< 0.001; three studies; 99 679 oocytes thawed; *I*^2^ = 91.6%, very low quality evidence) ([@dmw038C38]; [@dmw038C72]; [@dmw038C47]).

Oocyte slow-freezing versus fresh oocytes: clinical outcomes {#dmw038s9b}
------------------------------------------------------------

Analyses of the cohort studies ([@dmw038C15]; [@dmw038C12]; [@dmw038C123]) in which sibling oocytes were not randomized to be slow-frozen or used fresh revealed lower LBRs per cycle with slow-freezing (RR = 0.49, 95% CI: 0.39--0.60; *P* \< 0.0001; three studies; 990 and 2271 cycles; *I*^2^ = 0.0%, very low quality evidence) ([Supplementary Fig. S1a](#sup1){ref-type="supplementary-material"}), lower LBRs per transfer (RR = 0.55, 95% CI: 0.44--0.68; *P* \< 0.0001; three studies; 799 and 2046 cycles; *I*^2^ = 0.0%, very low quality evidence), and lower LBRs per utilized oocyte (RR = 0.26, 95% CI: 0.21--0.32; *P* \< 0.0001; three studies; 5513 and 6670 cycles; *I*^2^ = 0.0%, very low quality evidence) when slow-freeze was compared to fresh oocytes.

The CPR per cycle (RR = 0.42, 95% CI: 0.31--0.58; *P* \< 0.0001; five studies, 1809 and 3323 cycles, slow-freezing versus fresh, respectively; *I*^2^ = 64.5%, very low quality evidence) ([Supplementary Fig. S1b](#sup1){ref-type="supplementary-material"}), the CPR per transfer (RR = 0.45, 95% CI: 0.29--0.65, five studies; *P* \< 0.0001; 1534 and 2989 transfers; *I*^2^ = 78.5%, very low quality evidence) and the CPR per utilized oocytes (RR = 0.29, 95% CI: 0.25--0.35, four studies; 6600 and 9115 oocytes, slow-freezing versus, fresh, respectively; *P* \< 0.0001; *I*^2^ = 4.8%, very low quality evidence) were all in favor of fresh oocytes as compared to slow-frozen oocytes ([@dmw038C15]; [@dmw038C69]; [@dmw038C11],[@dmw038C12]; [@dmw038C123]). Each utilized slow-frozen oocyte had a 2.27% (150/6600) likelihood of resulting in a pregnancy in the population of women studied.

Oocyte vitrification versus fresh oocytes: clinical outcomes {#dmw038s9c}
------------------------------------------------------------

Analysis of a single RCT ([@dmw038C20]) revealed no evidence for a difference in ongoing CPR between the two groups when results were expressed per woman randomized (RR = 1.03, 95% CI: 0.87--1.21; *P* = 0.744, 300 women in each group; moderate quality evidence), per cycle (RR = 1.01, 95% CI: 0.86--1.18; *P* = 0.934; 267 versus 259 cycles vitrification versus fresh, respectively; moderate quality evidence) or per utilized oocyte (RR = 1.02, 95% CI: 0.82--1.26; *P* = 0.873; 3286 versus 3185 oocytes, vitrification versus fresh, respectively; moderate quality evidence).

The combined analysis of the cohort studies and the RCTs in which sibling oocytes were randomized to be vitrified or used fresh ([@dmw038C108]; [@dmw038C91]; [@dmw038C113]) revealed no evidence of a difference between cycles using exclusively vitrified versus fresh oocytes for LBR per cycle (RR = 1.04, 95% CI: 0.61--1.76, *P* = 0.892; three studies; 171 and 171 cycles, vitrification versus fresh, respectively; *I*^2^ = 52.3%; very low quality evidence) ([Supplementary Fig. S2](#sup1){ref-type="supplementary-material"}), LBR per oocyte utilized (RR = 2.35, 95% CI: 0.29--19.3, *P* = 0.427; two studies; 378 and 367 oocytes, vitrification versus fresh, respectively; *I*^2^ = 58.5%; very low quality evidence) ([@dmw038C91]; [@dmw038C113]), or LBR per transfer (RR = 1.10, 95% CI: 0.64--1.88, *P* = 0.730; three studies; 166 and 170 transfers, vitrification versus fresh, respectively, *I*^2^ = 54.6%; very low quality evidence). The two groups were also similar for CPR per cycle (RR = 0.94, 95% CI: 0.81--1.10; *P* = 0.457; eight studies; 526 and 892 cycles, vitrification versus fresh, respectively; *I*^2^ = 22.9%, very low quality evidence) ([@dmw038C108]; [@dmw038C4]; [@dmw038C3]; [@dmw038C98]; [@dmw038C115]; [@dmw038C43]; [@dmw038C91]; [@dmw038C113]); CPR per transfer (RR = 0.97, 95% CI: 0.81--1.16; *P* = 0.714; seven studies, 477 and 754 transfers, vitrification versus fresh, respectively; *I*^2^ = 38.1%, very low quality evidence) ([@dmw038C108]; [@dmw038C4]; [@dmw038C3]; [@dmw038C115]; [@dmw038C43]; [@dmw038C91]; [@dmw038C113]); and CPR per oocyte utilized (RR = 1.16, 95% CI: 0.57--2.69; *P* = 0.654; six studies; 1759 and 3832 oocytes, vitrification versus fresh, respectively; *I*^2^ = 89.5%, very low quality evidence) ([@dmw038C4]; [@dmw038C3]; [@dmw038C115]; [@dmw038C43]; [@dmw038C91]; [@dmw038C113]). Each utilized vitrified oocyte had an 8.36% (147/1759) likelihood of resulting in a pregnancy in the population of women studied.

Embryo slow-freezing versus vitrification {#dmw038s9d}
-----------------------------------------

### Slow-freezing versus vitrification: CPR {#dmw038s9d_1}

Given the limited number of RCTs available, results obtained in three RCTs with slow-freezing/thawing versus vitrification/warming for cleavage-stage embryos and blastocysts ([@dmw038C58]; [@dmw038C96]; [@dmw038C27]) were pooled. Overall, 638 warming/thawing cycles (vitrification: *n*= 247; slow-freezing: *n* = 391) were included. Data from pronuclear-stage warming cycles were not available. A higher CPR per cycle was obtained with embryo vitrification compared with slow-freezing though this was of borderline statistical significance (RR = 1.89, 95% CI: 1.00--3.58; *P* = 0.051, 638 cycles, three RCTs; *I*^2^ = 71.9%, low quality evidence, Fig. [3](#dmw038F3){ref-type="fig"}a). However, a significant difference in favor of vitrification was observed when CPR per embryo transfer was calculated (RR = 1.51, 95% CI: 1.03--2.23; *P* =  0.036; 488 embryo transfers; three RCTs; *I*^2^ = 35%, low quality evidence, Fig. [3](#dmw038F3){ref-type="fig"}b).

![Comparison of slow-freezing versus vitrification: embryos. (a) Comparison of slow-freezing versus vitrification on CPR/cycle for cleavage-stage embryos and blastocysts: RCTs; (b) Comparison of slow-freezing versus vitrification on CPR/embryo transfer for cleavage-stage embryos and blastocysts: RCTs.](dmw038f03){#dmw038F3}

When pooling data from cohort studies ([@dmw038C63],[@dmw038C64]; [@dmw038C109]; [@dmw038C76]; [@dmw038C73]; [@dmw038C97]; [@dmw038C129]; [@dmw038C106]; [@dmw038C125]; [@dmw038C77]; [@dmw038C120]; [@dmw038C134]; [@dmw038C57]), there was a significantly higher CPR per cycle ([Supplementary Fig. S3a](#sup1){ref-type="supplementary-material"}), but not per transfer, with vitrification compared with slow-freezing (RR = 1.27, 95% CI: 1.05--1.55; *P* = 0.015; eight observational studies; 8391 cycles; *I*^2^ = 76.5%, very low quality evidence and RR = 1.07, 95% CI: 0.98--1.16; *P* = 0.16; 12 observational studies; 22 885 embryo transfers; *I*^2^ = 64.7%; very low quality evidence, respectively).

When restricting the analysis of observational studies to those including only cleavage-stage embryos ([@dmw038C63],[@dmw038C64]; [@dmw038C73]; [@dmw038C97]; [@dmw038C129]; [@dmw038C106]; [@dmw038C125]; [@dmw038C77]; [@dmw038C120]; [@dmw038C134]; [@dmw038C57]), there was no statistically significant difference in CPR per cycle or CPR per transfer with vitrification compared with slow-freezing (RR = 1.27, 95% CI: 1.00--1.55; *P* = 0.62; six observational studies; 7789 cycles; *I*^2^ = 78.8%, very low quality evidence and RR = 1.05, 95% CI: 0.95--1.16; *P* = 0.33; 10 observational studies; 17 448 embryo transfers; *I*^2^ = 67%; very low quality evidence, respectively).

When restricting the analysis of observational studies to those including only blastocyst stage embryos ([@dmw038C63],[@dmw038C64]; [@dmw038C109]; [@dmw038C76]), there was no statistically significant difference in CPR per cycle or CPR per transfer with vitrification compared with slow-freezing (RR = 1.51, 95% CI: 0.69--3.29; *P* = 0.31; two observational studies; 602 cycles; *I*^2^ = 78.8%, very low quality evidence and RR = 1.16, 95% CI: 0.89--1.50; *P* = 0.27; three observational studies; 5437 embryo transfers; *I*^2^ = 61.8%; very low quality evidence, respectively).

### Slow-freezing versus vitrification LBR {#dmw038s9d_2}

The LBR per cycle and per transfer was reported in only one RCT performed with embryos at the cleavage-stage ([@dmw038C27]), with higher rates observed for vitrification (RR = 2.28; 95% CI: 1.17--4.44; *P* =  0.016; 216 cycles; low quality evidence and RR = 1.862 95% CI: 0.97--3.58; *P* =  0.062; 179 embryo transfers; low quality evidence, respectively).

Only three observational trials reported LBR per cycle ([@dmw038C129]; [@dmw038C125]; [@dmw038C120]) ([Supplementary Fig. S3b](#sup1){ref-type="supplementary-material"}) and six reported LBR per transfer ([@dmw038C63],[@dmw038C64]; [@dmw038C129]; [@dmw038C125]; [@dmw038C77]; [@dmw038C120]; [@dmw038C57]). No differences were observed between vitrification and slow-freezing (RR = 1.05, 95% CI: 0.67--1.65; *P* = 0.831; 1621 cycles; *I*^2^ = 74.8%; very low quality evidence and RR = 1.03, 95% CI: 0.91--1.18; *P* = 0.62; 14 996 embryo transfers; *I*^2^ = 45.8%; very low quality evidence, respectively).

When restricting the analysis of observational studies to those including only cleavage-stage embryos ([@dmw038C63],[@dmw038C64]; [@dmw038C73]; [@dmw038C97]; [@dmw038C129]; [@dmw038C106]; [@dmw038C125]; [@dmw038C77]; [@dmw038C120]; [@dmw038C134]; [@dmw038C57]), there was no significant difference in LBR per cycle or LBR per transfer with vitrification compared with slow-freezing (RR = 1.05, 95% CI: 0.67--1.65; *P* = 0.83; three observational studies; 1621 cycles; *I*^2^ = 74.8%, very low quality evidence and RR = 1.02, 95% CI: 0.87--1.20; *P* = 0.77; five observational studies; 10 153 embryo transfers; *I*^2^ = 52.7%; very low quality evidence, respectively).

When restricting the analysis of observational studies to those including only blastocyst stage embryos ([@dmw038C63],[@dmw038C64]; [@dmw038C109]; [@dmw038C76]), there was no significant difference in LBR per cycle with vitrification compared with slow-freezing (RR = 1.10, 95% CI: 0.87--1.40; *P* = 0.42; 1 observational study; 4843 cycles; very low quality evidence).

### Slow-freezing versus vitrification: embryo cryosurvival {#dmw038s9d_3}

Data were pooled from the seven RCTs ([@dmw038C58]; [@dmw038C51]; [@dmw038C96]; [@dmw038C133]; [@dmw038C6]; [@dmw038C39]; [@dmw038C27]) involving 3615 cleavage-stage embryos and blastocysts (slow-freezing: *n* = 2061; vitrification: *n*= 1554). The analysis revealed that vitrification was associated with a significant improvement in embryo cryosurvival (RR = 1.59, 95% CI: 1.30--1.93; *P* \< 0.001; *I*^2^ = 93%; moderate quality evidence) (Fig. [4](#dmw038F4){ref-type="fig"}).

![Comparison of slow-freezing versus vitrification on cryosurvival rate for cleavage-stage embryos and blastocysts: RCTs.](dmw038f04){#dmw038F4}

When restricted to cryosurvival of only cleavage-stage embryos, vitrification was superior to slow-freezing (RR = 1.74, 95% CI: 1.39--2.18; 2531 embryos; *P* \< 0.001; *I*^2^ = 92.2%; moderate quality evidence) ([@dmw038C96]; [@dmw038C133]; [@dmw038C6]; [@dmw038C39]; [@dmw038C27]). Post-warming cryosurvival rates of vitrified blastocysts were also higher than those observed with slow-freezing, but did not reach statistical significance (RR = 1.25: 95% CI: 0.93--1.67; *P* = 0.13; two RCTs; 1084 blastocysts; *I*^2^ = 82.2%, moderate quality evidence).

Twelve cohort studies ([@dmw038C63],[@dmw038C64]; [@dmw038C109]; [@dmw038C76]; [@dmw038C73]; [@dmw038C97]; [@dmw038C129]; [@dmw038C106]; [@dmw038C125]; [@dmw038C77]; [@dmw038C120]; [@dmw038C134]; [@dmw038C111]) with 64 982 cryopreserved pronuclear stage, cleavage-stage embryos or blastocysts were identified. The pooled data showed that vitrification was associated with a significant improvement in embryo cryosurvival (RR = 1.12, 95% CI: 1.07--1.18; *P* \< 0.001; *I*^2^ = 98.6% very low quality evidence) ([Supplementary Fig. S4](#sup1){ref-type="supplementary-material"}). When stratified by embryo stage, the cryosurvival rates favored vitrification for both cleavage-stage embryos (RR = 1.14, 95% CI: 1.07--1.22; *P* \< 0.001; 10 cohort studies; 49 200 embryos; *I*^2^ = 99%; very low quality evidence) and blastocysts (RR = 1.08, 95% CI: 1.02--1.15; *P* = 0.005; three cohort studies; *I*^2^ = 70.0%, very low quality evidence).

Discussion {#dmw038s10}
==========

The principal findings of this systematic review and meta-analysis support vitrification as being superior to slow-freezing for cryopreservation of both human oocytes and embryos in clinical ART. While the quality of the evidence for clinical outcomes comparing the two cryopreservation methods was mostly low and based on clinical pregnancy, rather than live-birth, that for post-thaw cryosurvival of oocytes and embryos was moderate.

The introduction of vitrification over the last decade and its extensive application has improved human oocyte and embryo cryosurvival rates and clinical outcomes after replacement of embryos cryopreserved at different stages of development. As shown in this study, recent evidence has revealed that this technique has closed the gap between fresh and cryopreserved oocytes in good-prognosis patients. However, although vitrification has allowed a substantial improvement in oocyte cryosurvival, when applied in an unselected population of patients (e.g. as a result of law) the clinical outcomes remained generally low (Fig. [2](#dmw038F2){ref-type="fig"}b). For embryo and blastocyst cryosurvival, available data suggest an improvement with the use of vitrification compared to slow-freezing, albeit over a wide range (30--93%). Accordingly, a typical laboratory could improve from \~60% embryo cryosurvival rate using slow-freezing to 78--100% embryo cryosurvival rate using vitrification. A beneficial treatment effect was also identified in RCTs for CPRs and LBRs per embryo and/or blastocyst warming cycle and per transfer.

Due to the improved cryosurvival outcomes with vitrification ([@dmw038C36]; [@dmw038C5]) many laboratories worldwide have completely replaced slow-freezing with vitrification. It is therefore unlikely that additional prospective comparisons with current protocols will be performed.

The optimized oocyte/embryo/blastocyst cryosurvival rates and clinical outcomes achieved with the use of vitrification have important clinical implications, which together allow a personalized approach in the care of different patient populations (Fig. [5](#dmw038F5){ref-type="fig"}).

![Clinical implications related to optimization of cryopreservation in IVF.](dmw038f05){#dmw038F5}

Contribution of cryopreservation to the cumulative LBR {#dmw038s10a}
------------------------------------------------------

Cryopreserved embryo transfers contribute substantially to the total success rate of an IVF cycle. Cumulative live birthrate (CLB) is defined as the likelihood of having an offspring after the utilization of all retrieved oocytes and associated embryos, thereby involving the transfer of fresh as well as all cryopreserved embryos. CLB is acknowledged as the most appropriate outcome measure in IVF to be used by practitioners and health administrators (Tiitinen *et al*., 2001). It has been estimated that in Europe in 2011 cryopreservation contributed to the overall LBR by 4% (LBR increasing from 19.7% with only fresh cycles to 24.0% including cryo-cycles) ([@dmw038C62]). In countries where cryopreservation is systematically applied, the contribution is even more apparent: Finland +13.4%, Switzerland +10.2% and Australia and New Zealand +13.5% ([@dmw038C80]; [@dmw038C62]). These data reflect improvements obtained in embryo culture, cryopreservation technologies and/or the adoption of a more conservative embryo transfer policy (i.e. when fewer embryos are transferred in fresh cycles, more are available for cryopreservation).

Embryo transfer policy and cryopreservation {#dmw038s10b}
-------------------------------------------

Considerable differences exist in embryo transfer policies across the world. Where not legally restricted, the number of embryos transferred simultaneously depends upon clinical decision-making, reimbursement strategies and other financial considerations and competency in cryopreservation technologies. Despite a general trend towards transferring fewer embryos ([@dmw038C18]), the mean percentage of single embryo transfers was only 27% in Europe in 2011 ([@dmw038C62]) and 17% in the USA ([@dmw038C14]). On the other hand, in Australia and New Zealand, single embryo transfer is performed in more than 75% of cycles ([@dmw038C80]). The incidence of multiple pregnancies, an unavoidable outcome of IVF when more than one embryo is transferred, is strongly correlated to the embryo transfer policy and varies from 19.8% in USA ([@dmw038C14]) and 19.2% in Europe ([@dmw038C62]) to 6.5% in Australia and New Zealand ([@dmw038C80]).

The main reasons for transferring more than one embryo are associated with the relative low efficiency of IVF, the poor prediction for embryo implantation potential and concerns regarding the quality of cryopreservation programmes. Other motivations are also related to the emotional and financial burden of ART treatment and lack of strong guidelines or regulatory bodies concerning embryo transfer policy ([@dmw038C136]). In this context, it is clear that improvements in embryology technologies, including embryo assessment and cryopreservation protocols, are essential for promoting single embryo transfer policies with an aim to reduce the maternal and neonatal risks associated with multiple gestations. Of note, elective single embryo transfer policy combined with enhanced embryo selection and vitrification is also a realistic option in poor-prognosis patients of advanced maternal age ([@dmw038C116]).

IVF cycle segmentation {#dmw038s10c}
----------------------

A new strategy, called 'cycle segmentation', has recently been proposed that comprises a planned 'freeze all' of all oocytes and/or embryos. In this setting ovarian stimulation is optimized, including final oocyte maturation triggering with GnRH agonist in an antagonist cycle, all oocytes and/or embryos are cryopreserved (segment A) and later transferred to a receptive endometrium in a subsequent cycle (segment B) ([@dmw038C31]). This approach has been tested with cryopreserved oocytes, pronuclear-stage and/or cleaved embryos in patients at risk of ovarian hyperstimulation syndrome (OHSS) ([@dmw038C45],[@dmw038C46]; [@dmw038C50]). With this strategy, the risk of OHSS can be almost eliminated ([@dmw038C41]; [@dmw038C131]).

Furthermore, transfer of exclusively cryopreserved single blastocysts in a population-based cohort study was found to decrease the risk of ectopic pregnancy ([@dmw038C75]) and increase IVF success rates with no increase in adverse perinatal outcomes ([@dmw038C74]). Improvements of clinical and ongoing pregnancy rates with the use of cryopreserved compared to fresh embryos have been reported in a recent meta-analysis ([@dmw038C101]). Additionally, similar efficacy was found in an RCT comparing outcomes following fresh transfer to that following freeze-all at either the blastocyst or the pronuclear-stage ([@dmw038C104]). Although cryopreservation cannot guarantee the survival of all embryos, these results clearly underscore the utility of cryopreservation in increasing the safety of IVF treatments, especially among high-responder patients, without affecting the cumulative pregnancy rate.

Cryopreservation and enhanced embryo evaluation {#dmw038s10d}
-----------------------------------------------

Embryo evaluation continues to be performed primarily by morphological assessment and/or morphokinetic analysis at different stages of development. However, static and dynamic morphological evaluations have limited clinical value ([@dmw038C48]; [@dmw038C95]; [@dmw038C56]). Significant improvements in implantation rates in different patient populations have been obtained by the introduction of chromosomal aneuploidy testing at the blastocyst stage ([@dmw038C40]; [@dmw038C67]). This strategy combines different procedures including blastocyst culture, biopsy and cryopreservation. The improvements in cryosurvival rates achieved with vitrification of biopsied blastocysts ([@dmw038C34]; [@dmw038C132]) have provided an important contribution to the widespread implementation of this technology. Future challenges in embryology will deal with further enhancement of embryo evaluation beyond aneuploidy testing and to identify the patient populations best served by such testing. Several studies are currently ongoing that investigate correlations among '-omic' profiling, metabolism, spent culture media analysis and embryo quality (reviewed in [@dmw038C42]). These studies offer promise in the coming years to increase the predictive power for implantation. The availability of reliable vitrification protocols for cryopreservation allows an extension of time available for embryo evaluation by such indirect measures, thereby affording a potential for implementation of new validated approaches for embryo selection.

New possibilities related to oocyte cryopreservation {#dmw038s10e}
----------------------------------------------------

Oocyte cryopreservation is a relatively new technology in ART but has already important indications. One of the most common applications of oocyte cryopreservation is for oocyte donation programmes. The introduction of oocyte banks offers different advantages including reduced waiting time, no need for patient synchronization, improved safety to prevent disease transmission and the possibility to increase donor pools. The increased availability of vitrified donor eggs has, in turn, allowed the widespread application of oocyte donation and the implementation of new forms of collaboration between centres (even when located in different countries). For example, an egg bank may provide donor evaluation and screening, ovarian stimulation, oocyte retrieval and cryopreservation, and then release these cryopreserved donor oocytes for recipient use at associated IVF clinics ([@dmw038C86]). Consequently, oocyte vitrification has provided important benefits for patients requiring donation, especially in those countries where there is a lack of donors.

Oocyte cryopreservation can be used as a new strategy to accumulate oocytes in poor-responder patients ([@dmw038C23]). It is also a back-up procedure, which can be performed in case of failure to obtain a semen sample on the day of oocyte retrieval.

The developments in oocyte cryopreservation after the introduction of vitrification have also increased incentives to offer fertility preservation for patients receiving gonadotoxic therapies for cancer or other medical diseases ([@dmw038C35]; [@dmw038C30]). The possibility of preserving oocytes is of considerable importance in this context. Oocyte cryopreservation, instead of the use of male-partner/donor sperm to create embryos, allows the possibility of reproductive autonomy in women without partners at the time when their fertility preservation is desired ([@dmw038C99]). Finally, oocyte vitrification can also be used for elective fertility preservation for women who are conscious of the decline in oocyte quality and quantity with advancing maternal age but who are not ready to become pregnant ([@dmw038C138]).

Of note, when oocyte cryopreservation is imposed by law restrictions and applied to an unselected population of infertile patients the clinical outcomes are compromised.

Standardization of protocols and automation {#dmw038s10f}
-------------------------------------------

Unlike slow-freezing, vitrification does not require a programmable freezing machine to provide specific cooling parameters. The technique is exclusively manual and is thus operator dependent. Furthermore, different commercial kits for vitrification are available and differ with respect to the solutions and devices utilized. Vitrification effectiveness may thus be highly variable and dependent on the protocols and experience of a laboratory. The heterogeneity of methods applied can create challenges with transportation of vitrified samples between laboratories using different cryoprotectant mixtures and/or vitrification devices. A rigorous process of standardization is therefore advocated. Comparative studies should be undertaken to establish best practices that would then be adopted universally (as occurred for slow-freezing 30 years ago). Indeed, attempts to promote standardization, consistency and efficiency are already underway with the introduction of automation ([@dmw038C100]). However, this approach requires considerable financial investment and its implementation is thus still limited.

Obstetric and perinatal outcomes {#dmw038s10g}
--------------------------------

Although cryopreservation of oocytes and embryos is now a well-established procedure, long-term follow-up studies of children are still sparse. Data from systematic reviews and individual cohort studies are mostly reassuring, suggesting that pregnancies obtained from a cryopreserved oocyte and/or embryo transfer are not associated with increased perinatal risks compared with those resulting from fresh embryo transfer ([@dmw038C124]; [@dmw038C16]; [@dmw038C87]; [@dmw038C126]; [@dmw038C20]; [@dmw038C92]; [@dmw038C93]; [@dmw038C79]; [@dmw038C70]; [@dmw038C77]; [@dmw038C24]; [@dmw038C7]; [@dmw038C28]; [@dmw038C72]). Obstetric and perinatal complications (e.g. antepartum haemorrhage, preterm birth, small for gestational age, low birthweight and perinatal mortality) are even lower when frozen or vitrified embryos are replaced, likely as a consequence of the natural uterine environment that may better support early placentation and embryogenesis ([@dmw038C126]; [@dmw038C79]; [@dmw038C7]). Moreover, further reassuring evidence comes from studies evaluating the safety of oocyte vitrification in oocyte donation programmes ([@dmw038C16]; [@dmw038C87]; [@dmw038C20]; [@dmw038C24]; [@dmw038C28]) and in fertility preservation patients ([@dmw038C81]).

Conclusions {#dmw038s11}
===========

Cryopreservation is an essential component in the treatment of patients undergoing ART and should be optimized in every IVF laboratory, as it allows for increased cumulative LBRs and offers the possibility to reduce multiple gestations and OHSS risk. According to the available evidence appraised in this systematic review and meta-analysis, vitrification is the best strategy for cryopreservation of all developmental stages from mature oocyte to embryos at the blastocyst stage. As this technique significantly increases oocyte and embryo cryosurvival rates when compared to slow-freezing, it has led to an improvement in clinical outcomes in cryopreserved cycles and also has made fertility preservation and donor oocyte banks a viable option for patients. Furthermore, it allows for reliable segmentation of the IVF cycle by temporally disconnecting the stimulation process from embryo transfer; consequently, this affords additional time for new invasive and non-invasive methods of embryo selection. Finally, if standardized and/or automated, the consistency and efficiency of the technique would likely be assured across all laboratories.
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